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ABSTRACT (338/350 words) 30 
 31 
Importance 32 
Patient-reported outcome (PRO) data from clinical trials can provide valuable evidence to inform 33 
shared-decision making, labelling claims, clinical guidelines, and health policy; however, the PRO 34 
content of clinical trial protocols is often suboptimal. The SPIRIT (Standard Protocol Items: 35 
Recommendations for Interventional Trials) Statement was published in 2013 and aims to improve the 36 
completeness of trial protocols by providing evidence-based recommendations for the minimum set of 37 
items to be addressed, but does not provide PRO-specific guidance. 38 
 39 
Objective 40 
To develop international, consensus-based, PRO-specific protocol guidance: the SPIRIT-PRO 41 
extension. 42 
 43 
Design, Setting, and Participants 44 
The SPIRIT-PRO Extension was developed following the Enhancing QUAlity and Transparency Of 45 
health Research (EQUATOR) Network’s methodological framework for guideline development. This 46 
included: (i) a systematic review of existing PRO-specific protocol guidance to generate a list of 47 
candidate PRO-specific protocol items (published 2014); (ii) refinements to the list and removal of 48 
duplicate items by the International Society for Quality of Life Research (ISOQOL) PROtocol Checklist 49 
Taskforce; (iii) an international stakeholder survey of: clinical trial research personnel, PRO 50 
methodologists, health economists, psychometricians, patient advocates, funders, industry 51 
representatives, journal editors, policy makers, ethicists and researchers responsible for evidence 52 
synthesis (distributed by 38 international partner organizations, October 2016); (iv) an international 53 
Delphi exercise (n=137 invited; October 2016 to February 2017)and consensus meeting (n=30 54 
invited; May 2017). Prior to voting, consensus meeting participants were informed of the results of the 55 
Delphi exercise and given data from structured reviews evaluating the PRO protocol content of three 56 
defined samples of trial protocols.  57 
   58 
Results 59 
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The systematic review identified 162 PRO-specific protocol recommendations from 54 sources. The 60 
ISOQOL Taskforce (n=21) reduced this to 56 items, which were considered by 138 international 61 
stakeholders and 99 Delphi panelists. The final wording of the SPIRIT-PRO Extension was agreed at 62 
a consensus meeting (n=29 participants) and reviewed by external stakeholders during a consultation 63 
period. Eleven extensions and five elaborations to the SPIRIT 2013 checklist are recommended for 64 
inclusion in clinical trial protocols where PROs are a primary or key secondary outcome. Extension 65 
items focused on PRO specific issues relating to the: trial rationale, objectives, eligibility criteria, 66 
concepts used to evaluate the intervention, timepoints for assessment, PRO instrument selection and 67 
measurement properties, data collection plan, translation to other languages, proxy completion, 68 
strategies to minimise missing data and whether PRO data will be monitored during the study to 69 
inform clinical care. 70 
 71 
Conclusions and relevance 72 
These guidelines provide recommendations for items that should be addressed and included in 73 
clinical trial protocols in which PROs are a primary or key secondary outcome. Improved design of 74 
clinical trials including PROs could help ensure high-quality data that may inform patient-centered 75 
care. 76 
 77 
 78 
 79 
 80 
 81 
 82 
 83 
  84 
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INTRODUCTION  85 
Clinical trial protocols are essential documents that describe the study design and conduct.  A 86 
protocol should provide sufficient detail to enable funders, reviewers and ethics committees to 87 
appraise the trial’s scientific, methodological and ethical rigor and for the research team to deliver a 88 
high quality study.1,2 Although they serve as the foundation for study planning, conduct, reporting, and 89 
appraisal, trial protocols vary greatly in content and quality.1,2 To address this issue, the SPIRIT 90 
(Standard Protocol Items: Recommendations for Interventional Trials) Statement was published in 91 
2013.1,2  SPIRIT provides an evidence-based list of items recommended for inclusion in trial protocols. 92 
It does not, however, provide specific guidance on protocol content relating to patient-reported 93 
outcomes (PROs), such as health-related quality of life (HRQOL) or patient-reported symptoms.  94 
 95 
The importance of PROs has been recognized by major international health policy and regulatory 96 
authorities and patients.3-5 PRO trial results, if captured in a scientifically rigorous way, may inform 97 
clinical decision-making6, pharmaceutical labelling claims4-5, product reimbursement and influence 98 
healthcare policy.6 Despite this, the quality of PRO content in many protocols is often suboptimal, 99 
regardless of the degree of adherence to SPIRIT.7-9 Because PROs are intrinsically subjective and 100 
require completion by patients within a specific time-frame, they present a range of scientific and 101 
logistical challenges for researchers and data collection staff.10-12 Comprehensive planning and 102 
instruction in the protocol can mitigate many PRO-specific issues through trial conduct, and 103 
subsequent analysis and reporting. Protocol developers, particularly those not familiar with PRO 104 
methodology, may benefit from explanation of PRO-specific aspects to facilitate improvements in 105 
content.  106 
 107 
The aim of this international project was to develop an evidence-based extension of the SPIRIT 2013 108 
statement, identifying additional PRO items recommended for inclusion in clinical trial protocols 109 
(extensions) and to elaborate on the existing SPIRIT 2013 statement specifically as applied to PROs 110 
(elaborations).13 This article describes the methods used to gain consensus on each additional 111 
SPIRIT-PRO extension/elaboration, provides a brief explanatory rationale, and includes PRO specific 112 
items that may be included in supplemental trial documents. 113 
 114 
115 
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SPIRIT-PRO DEVELOPMENT METHODS  116 
The SPIRIT-PRO Extension was developed according to the Enhancing QUAlity and Transparency Of 117 
health Research (EQUATOR) Network’s methodological framework for guideline development 118 
(eFigure 1 in Supplement 1).14 This included: a systematic review of existing PRO-specific protocol 119 
guidance15; an international stakeholder survey; Delphi exercise and consensus meeting; followed by 120 
consultation on the final SPIRIT-PRO Extension.14 The systematic review comprised a search of 121 
MEDLINE, EMBASE, CINHAL and Cochrane Library databases (inception to February 2013) using 122 
the key words ‘Patient-Reported Outcomes’ or ‘Health-Related Quality of Life’ in combination with 123 
‘Guidance’, ‘Guidelines’ or ‘Checklist’. Further guidance documents were identified via Google, 124 
Google scholar, requests to members of the UK Clinical Research Collaboration registered clinical 125 
trials units, international experts and through citation and reference searches of included articles. 126 
Papers were deemed eligible if they contained guidance and/or a checklist on PRO related trial 127 
protocol content.15   128 
eFigure 1 summarizes the methods and participants involved in the development of SPIRIT-PRO, the 129 
numbers of candidate items considered at each step, and the flow towards the final set of items 130 
included in SPIRIT PRO.  eTable 1 in Supplement 1 outlines the participant characteristics. Patient 131 
partners contributed to the co-design of the research, grant application, have provided input 132 
throughout the study and are coauthors.    133 
 134 
Ethical Review of Study  135 
Ethical approval was provided by The University of Birmingham Ethical Review Board (Reference: 136 
ERN_16-0819). Participant information was provided to potential participants prior to survey 137 
completion and in advance of the consensus meeting. Survey participants provided electronic 138 
informed consent and written consent was provided by the consensus meeting participants. 139 
 140 
Systematic review of existing PRO-specific protocol guidance and development of the Delphi 141 
and Stakeholder Survey 142 
Our systematic review of existing PRO protocol guidance identified 162 PRO-specific protocol 143 
recommendations from 54 sources15. The International Society for Quality of Life Research (ISOQOL) 144 
PROtocol Checklist Taskforce comprising international experts in PROs research and clinical trials 145 
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(eTable 1 and Acknowledgments, Supplement 1) reduced this list to 56 candidate items by removing 146 
or merging duplicate items, meaning 56 items were included in the subsequent identical Stakeholder 147 
and Delphi surveys. Survey participants were asked to rate the importance of including each of the 56 148 
candidate items in the final SPIRIT-PRO Extension using a 9-point scale: ‘not important’ (1-3), 149 
‘important but not critical’ (4-6) and ‘critical’ (7-9). Respondents provided separate ratings according to 150 
whether a PRO was included as a primary versus secondary outcome in a trial. 151 
 152 
International stakeholder survey 153 
In 2016, 38 international partner organizations (detailed in Supplement 1) invited their members with 154 
relevant expertise to complete an online survey. From these organizations, a total 138 participants 155 
provided anonymized survey results which informed round 2 of the Delphi panel exercise.  156 
 157 
International Delphi exercise 158 
In parallel with the international stakeholder survey, key experts (n=114)  from the ISOQOL PROtocol 159 
Checklist Taskforce, international partner organizations and other experts known or recommended to 160 
the SPIRIT-PRO Executive were invited to join an international, multidisciplinary expert Delphi Panel. 161 
Delphi panelists were advised not to complete the stakeholder survey to avoid double counting of 162 
results. Delphi panelists (n=99) completed 2 rounds of online surveys and results informed the 163 
subsequent international consensus meeting. Data collected from the stakeholder and round 1 Delphi 164 
surveys were anonymized and the item-level results were provided to the Delphi panel for 165 
consideration prior to voting in Delphi round 2. Further details and the results of the Delphi and 166 
stakeholder surveys are available on the study website.16  167 
 168 
Consensus meeting 169 
Using the Stakeholder and Delphi survey results, the SPIRIT-PRO Operations Team (MC, DK, RMB, 170 
AS, MK) mapped the 56 candidate SPIRIT-PRO items to corresponding SPIRIT-2013 items, revising 171 
wording as needed to address stakeholder/Delphi panelist comments. For each candidate SPIRIT-172 
PRO item, the Operations Team presented the consensus meeting delegates with recommendations 173 
for SPIRIT ‘elaborations’ and ‘extensions’ (see Box for definitions ) based on a decision tree (eFigure 174 
2 in Supplement 1), which incorporated information drawn from the Delphi survey and three separate 175 
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reviews of PRO protocol content (n= 207 protocols): protocols from the UK National Institute for 176 
Health Research (NIHR) Health Technology Assessment (HTA) programme7;  cancer trial protocols 177 
from the NIHR8 and international ovarian cancer protocols9. Twenty-nine participants purposively 178 
sampled from the Delphi panel attended the two-day consensus meeting hosted by the University of 179 
Birmingham, England, in May 2017 (eTable 1). The meeting was designed to seek consensus on the 180 
content of the SPIRIT-PRO Extension. Meeting participants were invited to consider the focus of the 181 
guidance and agreed that it should apply to trials where PROs are a primary or key secondary 182 
outcome (as defined in Glossary).  Delegates anonymously voted using Turning point© (v5.1, 183 
2012)/Responseware© software to either: include the candidate item as recommended; exclude the 184 
item; or initiate further discussion.  Key research evidence (Round 2 Delphi survey results and 185 
systematic review data) presented to meeting participants is provided in Supplement 2.  Consensus 186 
meeting participants were also invited to review Delphi results for recommendation on where to 187 
include each of the candidate items in addition to, or instead of, the trial protocol (eg, 188 
guidance/training for trial staff, information/guidance for study participants, or the statistical analysis 189 
plan (SAP).  190 
 191 
Final consultation 192 
Following the consensus meeting, attendees commented on wording and agreed on the penultimate 193 
SPIRIT-PRO Extension content. Broader feedback on the final guidance was sought from our Delphi 194 
panel and international partners during a three week consultation period. Final edits in response to 195 
feedback were made by the Operations Team and agreed by the SPIRIT-PRO Group. 196 
 197 
RESULTS 198 
 199 
SPIRIT-PRO Checklist Items and Explanation 200 
The final SPIRIT-PRO Extension recommends that, in conjunction with existing SPIRIT 2013 items, 201 
16 items should be routinely addressed in all clinical trial protocols where PROs are a primary or key 202 
secondary outcome (11 extensions; 5 elaborations). Further information regarding the SPIRIT 2013 203 
items is detailed in references1,2. Table 1 lists the items of the SPIRIT 2013 checklist (left column) and 204 
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the SPIRIT-PRO extensions/elaborations (right-hand column). The 11 extensions and 5 elaborations 205 
incorporated 34 of the original 56 candidate items, as 27 items were merged by consensus. One new 206 
item was generated through discussion (SPIRIT-18a-PRO Extension (iii)). Definitions of key terms are 207 
contained in the Glossary (Box). Below we provide a brief explanation for each PRO 208 
extension/elaboration, including references to supporting empirical evidence where available (items 209 
6a through 22). Item 5a was not supported by empirical evidence but was supported by expert opinion 210 
drawn from our systematic review of PRO protocol guidance15, and in line with the development of the 211 
original SPIRIT statement1, 2 , was underpinned by a strong pragmatic rationale. 212 
 213 
Administrative Information 214 
Specify the individual(s) responsible for the PRO content of the trial protocol: SPIRIT-5a-PRO 215 
Elaboration. Explanation: Providing information (eg, name, affiliation, contact details) on who wrote 216 
the PRO specific aspects of the trial protocol promotes transparency and accountability, and identifies 217 
the appropriate point of contact for resolution of any PRO specific queries. Where patients have 218 
actively contributed to this process, this should be documented as per recent guidance for the 219 
reporting of patient and public involvement.17 220 
 221 
Describe the PRO specific research question and rationale for PRO assessment, and 222 
summarize PRO findings in relevant studies: SPIRIT-6a-PRO Extension. Explanation: Inclusion of 223 
PROs in a trial requires careful consideration and planning. A clearly defined question helps with 224 
selection of measures and specification of hypotheses and analyses. Evidence suggests that many 225 
trials include PROs without specifying the PRO-specific research question, and without a rationale or 226 
any reference to PROs in related studies.7-9 Consequently, staff and patients may not understand why 227 
PROs are being assessed, and missing data may result.7-12 When the PRO is a secondary outcome, 228 
a brief rationale may be adequate.  229 
 230 
State specific PRO objectives or hypotheses (including relevant PRO concepts/domains): 231 
SPIRIT-7-PRO Extension. Explanation: PRO measures may be multidimensional (eg, HRQOL) or 232 
unidimensional (eg, specific symptoms such as pain) and assessments may be scheduled at several 233 
time points during a trial. Pre-specification of objectives and hypotheses encourages identification of 234 
 9 
 
key PRO domains and time-points, reducing the risk of multiple statistical testing and selective 235 
reporting of PROs based on statistically significant results (see also PRO elaboration 20a below).4  236 
 237 
Methods: Participants, interventions, and outcomes 238 
Specify any PRO-specific eligibility criteria (eg, language/reading requirements or pre-239 
randomization18 completion of PRO). If PROs will not be collected in the entire study sample, 240 
provide a rationale and describe the method for obtaining the PRO subsample: SPIRIT-10-PRO 241 
Extension. Explanation: Any PRO-specific eligibility criteria should be considered at the design stage 242 
of the trial and clearly specified in the protocol. In large trials, sufficient power may be achieved by 243 
collecting PROs from a representative subset of participants; whilst in some trials it may not be 244 
possible to collect PROs in the entire population (eg, due to non-availability of validated 245 
questionnaires in all languages)8; in such instances the rationale for the sampling method should be 246 
described. 247 
    248 
Specify the PRO concepts/domains used to evaluate the intervention (eg, overall HRQOL, 249 
specific domain, specific symptom) and, for each one, the analysis metric (eg, change from 250 
baseline, final value, time to event) and the principal time point or period of interest: SPIRIT-251 
12-PRO Extension. Explanation: The PRO concepts/domains and time points for assessment should 252 
closely align with the trial objectives and hypotheses. Because of the risk of multiple statistical testing, 253 
the domain(s) and principal time point(s) for analyses should be specified a priori.4,19  254 
 255 
Include a schedule of PRO assessments, providing a rationale for the time points, and 256 
justifying if the initial assessment is not pre-randomization. Specify: time windows; whether 257 
PRO collection is prior to clinical assessments; and if using multiple questionnaires, whether 258 
order of administration will be standardized: SPIRIT-13-PRO Extension. Explanation: Provision of 259 
an easy to follow schedule will assist staff and may help reduce missing data.18 Collecting PRO data 260 
prior to randomization helps ensure an unbiased baseline assessment, and if specified as an eligibility 261 
criterion, ensures data completeness. This is important as baseline PRO data are often used as a 262 
covariate in analyses and is essential to calculating change from baseline.  Completion of PROs prior 263 
to clinical assessments (as these may influence patient responses) and standardization of the order of 264 
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questionnaire administration are advised to help reduce measurement error.20 Allowable time 265 
windows for each scheduled PRO assessment should be specified to ensure that PRO data collection 266 
captures the impact of the clinical event(s) of interest. 267 
 268 
Where a PRO is the primary endpoint, state the required sample size (and how it was 269 
determined) and recruitment target (accounting for expected loss to follow-up). If sample size 270 
is not established based on PRO endpoint, then discuss the power of the principal PRO 271 
analyses: SPIRIT-14-PRO Elaboration. Explanation: In studies in which PROs are the primary 272 
outcome/endpoint, the target sample size will generally be based on an a priori sample size 273 
calculation for that endpoint.19 Ideally the criteria for clinical significance (eg, minimal important 274 
difference and/or responder definition) should be specified when known.21,22 If PROs are the 275 
secondary endpoint, researchers should specify whether the sample size provides sufficient power to 276 
test the principal PRO hypotheses.19  277 
 278 
Methods: Data collection, management, and analysis 279 
Justify the PRO instrument to be used, and describe domains, number of items, recall period, 280 
instrument scaling/scoring (eg, range and direction of scores indicating a good/poor 281 
outcome). Evidence of PRO instrument measurement properties, interpretation guidelines, and 282 
patient acceptability/burden should be provided or cited if available, ideally in the population 283 
of interest. State whether the measure will be used in accordance with any user manual and 284 
specify and justify deviations if planned: SPIRIT-18a(i)-PRO Extension. Explanation: The 285 
selection of PROs to be used in a clinical trial requires careful consideration. Ideally the measure 286 
should be validated in the target population.23 Consideration should be given to the number of 287 
questionnaires to be used, acceptability of the questions, and the likely patient burden (eg, time taken 288 
for completion and cognitive and/or emotional burden). Justification for the measures selected will 289 
help trial personnel understand why specific measures are being used.10 Questionnaires should be 290 
used in accordance with any existing user manuals to promote data quality and ensure standardized 291 
scoring, and any deviations should be described.    292 
 293 
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Include a data collection plan outlining the permitted mode(s) of administration (eg, paper, 294 
telephone, electronic, other) and setting (eg, clinic, home, other): SPIRIT-18a(ii)-PRO 295 
Extension. Explanation: It is important that both research personnel and trial participants understand 296 
how, when, and where PRO data will be collected in the study. Increasingly, electronic PRO 297 
assessment is undertaken in trials, so evidence of equivalence between different modes of 298 
administration should be considered.24 If electronic PRO measures contain only minor modifications 299 
with respect to the paper based versions, usability testing and cognitive debriefing may provide 300 
sufficient evidence of equivalence.24,25 The setting for PRO data collection should be described and 301 
standardized across trial arms and sites. 302 
 303 
Specify whether more than one language version will be used, and state whether translated 304 
versions have been developed using currently recommended methods: SPIRIT-18a(iii)-PRO 305 
Extension. Explanation: Multinational trials, or national trials involving participants with different 306 
languages, will require measures that have been translated, and culturally adapted where needed, 307 
using appropriate methodology.11,26 This may influence the selection of measure to be used, since 308 
inclusivity of participants can help ensure the generalizability of trial results.  Plans to use translated 309 
versions should be specified in the protocol, citing references where available. 310 
 311 
Where the trial context requires someone other than the trial participant to answer on their 312 
behalf (a proxy reported outcome), state and justify this. Provide/cite evidence of the validity 313 
of proxy assessment if available: SPIRIT-18a(iv)-PRO Extension. Explanation: In some contexts, 314 
eg, trials involving young children, or cognitively impaired participants, it may be necessary for 315 
someone other than the trial participant to respond on their behalf. Clear justification and specification 316 
of proxy reporting in the protocol will allow external reviewers to assess potential bias and will 317 
facilitate trial reporting in accordance with CONSORT-PRO.27 Evidence of the size and direction of 318 
proxy bias is a key aspect of the validity of proxy versions of PRO measures, informing valid 319 
interpretation and comparison of results. Note that the European Medicines Agency (EMA) state that 320 
‘in general proxy reporting should be avoided, unless the use of such proxy raters may be the only 321 
effective means of obtaining information that might otherwise be lost’.5 The US Food and Drug 322 
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Administration (FDA) also discourages the use of proxy reported outcomes to inform labelling claims, 323 
recommending observer reports instead.4   324 
 325 
Specify PRO data collection and management strategies for minimising avoidable missing 326 
data: SPIRIT-18b(i)-PRO Extension. Explanation: Missing data is a particular problem for PROs 327 
since it is often those participants with the poorest outcomes in a trial that fail to complete planned 328 
PRO assessments and data cannot be obtained retrospectively beyond the timeframe of interest or 329 
from medical records. This is a potentially significant source of bias, and may reduce trial power.28 It is 330 
important to note that not all missing PRO data is avoidable: patients have the right to decide not to 331 
complete questionnaires. Common reasons for avoidable missing PRO data are administrative errors, 332 
lack of explanation of the importance of PRO data, and overly-burdensome questionnaires. 333 
Addressing these in the protocol should help minimize avoidable missing data.  A recent systematic 334 
review provides a range of design, implementation and reporting strategies to help minimize and 335 
address missing PRO data.18 Examples of protocol content include: ensuring PRO endpoints and 336 
hypotheses are clearly defined and scientifically compelling, providing a rationale for PRO 337 
assessment, clearly specifying the PRO assessment time points, defining acceptable PRO 338 
assessment time windows, aligning PRO assessment time points to clinic visits (if clinically 339 
informative), minimizing patient burden, and specifying the importance of complete PRO data.18 340 
 341 
Describe the process of PRO assessment for participants who discontinue or deviate from 342 
their assigned intervention protocol: SPIRIT-18b(ii)-PRO Elaboration. Explanation: A clear plan 343 
for collection of PROs for trial participants who withdraw early from a study or who discontinue the 344 
intervention will help minimise bias,29 ensure staff collect all required PRO data in a standardized and 345 
timely way, and may assist ethical appraisal of the study.  346 
 347 
State PRO analysis methods including any plans for addressing multiplicity/type 1 (α) error: 348 
SPIRIT-20a-PRO Elaboration. Explanation: Many questionnaires, such as HRQOL measures, are 349 
multidimensional and therefore may yield several summary scores (eg, multiple domains and an 350 
overall score). Further, PROs are usually assessed at multiple time points. Statistical analysis of all 351 
domains and timepoints implies multiple hypothesis testing, which inflates the probability of false 352 
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positives (type 1 error, or ‘alpha’).19 This can be contained by pre-specifying the key PRO domain(s) 353 
or overall score of interest, and the principal time point(s). Any plans to address multiplicity, such as 354 
step-wise or sequential analyses, whereby multiple endpoints are tested in a defined sequence that 355 
contains the overall type 1 error to the desired level, or conventional non-hierarchical methods (eg, 356 
Bonferroni correction), should be specified a priori.4 The protocol should either fully address these 357 
issues, or provide a summary, with reference to where full details can be found (eg, in the statistical 358 
analysis plan (SAP)). 359 
 360 
State how missing data will be described and outline the methods for handling missing items 361 
or entire assessments (eg, approach to imputation and sensitivity analyses): SPIRIT-20c-PRO 362 
Elaboration. Explanation: There are two levels of missing PRO data: 1) patient completion of some, 363 
but not all items within an instrument; 2) absence of the entire PRO assessment. Whether and how 364 
missing items should be imputed is usually specified in an instrument’s scoring algorithm. When entire 365 
PRO assessments are missed, analysis requires assumptions about why those data were missing (ie, 366 
the missing data mechanism). There are a range of statistical approaches, each with specific 367 
assumptions. Inappropriate method selection may lead to potentially biased and misleading 368 
results.18,29 Common methods include complete case analysis, imputation (various approaches), a 369 
range of maximum likelihood modelling approaches, and sensitivity analysis.29 The protocol should 370 
acknowledge these issues, and address them in summary, with full detail provided in the SAP. 371 
 372 
Methods: Monitoring 373 
State whether or not PRO data will be monitored during the study to inform the clinical care of 374 
individual trial participants and, if so, how this will be managed in a standardized way. 375 
Describe how this process will be explained to participants, eg, in the participant information 376 
sheet and consent form: SPIRIT-22-PRO Extension. Explanation: Evidence suggests the 377 
monitoring and management of ‘PRO-alerts’ (psychological distress or physical symptoms evident 378 
from PRO responses that may require an immediate response) varies across and within trials.10,11,30  379 
In order to protect the interests of trial participants and minimize potential bias, it is important to 380 
specify plans for monitoring.31   If monitoring is not planned (for example in a low risk study where 381 
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alerts are not anticipated) then this should also be briefly stated in the protocol, the participant 382 
information sheet and consent form. Alternative support mechanisms for patients should be outlined. 383 
 384 
Supplementary trial documents 385 
Supplement 3 outlines additional items recommended for inclusion in other trial documentation such 386 
as the SAP, participant information sheet or in training/guidance documents for staff. 387 
 388 
DISCUSSION 389 
The SPIRIT-PRO Extension provides international consensus-based guidance on PRO-specific 390 
information that should be included in clinical trial protocols.  It comprises 16 items: 5 elaborations to 391 
existing SPIRIT 2013 items in the context of PROs, and 11 new extensions, for use alongside the 392 
existing SPIRIT 2013 guidance.1,2 It is important to note that these are minimum requirements, and 393 
that there may be value in including additional items in the protocol and/or in supplementary trial 394 
documents, as outlined in Supplement 3. While this guidance has been developed for trials where 395 
PROs are a primary or key secondary outcome we encourage protocol writers to consider use of this 396 
guidance in all trials or clinical research studies where PROs are collected, including if PROs are 397 
exploratory endpoints.  The guidance does not aim to be prescriptive regarding how information 398 
should be included, as this may vary depending on the research setting and local requirements. 399 
Further details of empirical evidence underpinning the SPIRIT-PRO items and examples for 400 
implementation will be provided in a future explanatory publication on the PROlearn32 and SPIRIT 401 
Initiative33 websites and will be facilitated through further development of the SPIRIT 2013 402 
implementation tool SEPTRE33 (SPIRIT Electronic Protocol Tool and Resource) and through 403 
dissemination via our international partners (see Supplement 1). Inclusion of PRO-specific protocol 404 
content will facilitate appraisal of the PRO elements by funders, reviewers, research ethics 405 
committees, and patient partners.  The SPIRIT-PRO Extension is intended to encourage and facilitate 406 
careful planning of PRO components of trials, and thereby improve PRO trial design. Consequently, 407 
this is expected to help staff and patients understand the rationale for PRO assessment, improve 408 
PRO data completeness and quality, facilitate high quality analysis and reporting, and ultimately 409 
improve the quality of the global PRO evidence base.  410 
 411 
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To maximize the benefit of PRO data in policy and practice, it is recommended that careful 412 
consideration be given to the selection of outcomes and measures34,35, analysis of PRO data,4,5,36 and 413 
transparent reporting in accordance with CONSORT-PRO.27 Patient and public involvement in all of 414 
these aspects can help to ensure that PRO selection and application is transparent, relevant and 415 
acceptable.37-38 Consistent with this philosophy, patient partners have been involved in all aspects of 416 
the development of the SPIRIT-PRO extension.37-38  Ultimately, high quality PRO trial results will help 417 
ensure that the patient’s voice is central to informing shared-decision making, labelling claims, clinical 418 
guidelines, and health policy, making patient-centered care a reality.  419 
 420 
Limitations 421 
Respondents to the stakeholder survey were self-selecting and Delphi and consensus meeting 422 
participants were purposively sampled based on their roles and expertise relating to PROs.  423 
Participants are therefore more likely to have more knowledge relating to PROs than broader 424 
research personnel.   425 
 426 
Conclusions 427 
The SPIRIT-PRO guidelines provide recommendations for items that should be addressed and 428 
included in clinical trial protocols in which PROs are a primary or key secondary outcome. Improved 429 
design of clinical trials including PROs could help ensure high-quality data that may inform patient-430 
centered care. 431 
 432 
 433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
 441 
 442 
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Glossary Box 
 
SPIRIT 
Standard Protocol Items: Recommendations for Interventional Trials1,2 
 
SPIRIT-PRO Extension Item 
An additional checklist item describing PRO protocol content to address an aspect of PRO assessment that is not adequately covered by SPIRIT, as judged by available evidence and expert 
opinion. 
 
SPIRIT Elaboration Item 
An elaboration of an existing SPIRIT item as applied to a specific context; in this instance, as applied to clinical trials assessing PROs. 
 
Patient-Reported Outcome (PRO) 
An outcome reported directly by patients themselves and not interpreted by an observer; PROs may include patient assessments of health status, quality of life, or symptoms.27 
 
Proxy-Reported Outcome 
‘A measurement based on a report by someone other than the patient reporting as if he or she is the patient.’4 
 
Health-Related Quality of Life (HRQOL) 
‘HRQOL is a multidimensional concept that usually includes self-report of the way in which physical, emotional, social, or other domains of well-being are affected by a disease or its 
treatment.’27 
 
Primary Outcome/ Endpoint  
The most important outcome in a trial, providing the most clinically relevant evidence directly related to the primary objective of the trial. 
 
Secondary Outcomes / Endpoint(s) 
These are outcomes pre-specified in the protocol to assess additional effects of the intervention. Some PROs may be identified as important or key secondary outcomes. 
 
‘Important’ or ‘Key’ Secondary Patient-Reported Outcomes / Endpoints 
Some PRO measures (particularly HRQOL measures) are multidimensional, producing several domain-specific outcome scales, e.g. pain, fatigue, physical function, psychological distress. For 
any particular trial, it is likely that a particular PRO or PRO domain(s) will be more relevant than others, reflecting the expected effect(s) of the trial intervention(s) in the target patient 
population. These relevant PRO(s) and/or domain(s) may additionally constitute the important or key secondary PROs (identified a priori and specified as such in the trial protocol and 
statistical analysis plan) and will be the focus of hypothesis testing. In a regulatory environment, these outcomes may support a labelling claim. Because these outcomes are linked with 
hypotheses (see CONSORT PRO Extension 2b)27, they may be subject to P value adjustment (or ‘alpha-spending’). Note: PROs may not only provide evidence of efficacy/effectiveness but 
may also be intended to capture and provide evidence of safety and tolerability (e.g. PRO-CTCAE).39 
 
Concept 
‘The specific measurement goal (ie, the thing that is to be measured by a PRO instrument). In clinical trials, a PRO instrument can be used to measure the effect of a medical intervention on 
one or more concepts. PRO concepts represent aspects of how patients function or feel related to a health condition or its treatment.’ 4 
 
Domain  
‘A subconcept represented by a score of an instrument that measures a larger concept comprised of multiple domains. For example, psychological function is the larger concept containing the 
domains subdivided into items describing emotional function and cognitive function.’4 
 
Instrument 
‘A means to capture data (ie, a questionnaire) plus all the information and documentation that supports its use. Generally, that includes clearly defined methods and instructions for 
administration or responding, a standard format for data collection, and well-documented methods for scoring, analysis, and interpretation of results in the target patient population.’4  
 
Item 
‘An individual question, statement, or task (and its standardized response options) that is evaluated by the patient to address a particular concept.’4 
 
Time window  
A pre-defined time frame before and after the protocol-specified PRO assessment time point whereby the result would still be deemed to be clinically relevant.40 
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Table 1 SPIRIT 2013* and SPIRIT-PRO Extension checklist: recommended items to address in a clinical trial protocol *It is strongly recommended 
that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol 
should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons “Attribution-NonCommercial-NoDerivs 
3.0 Unported” license and is reproduced by JAMA with their permission. #Indicates page numbers to be completed by authors during protocol development. 
 
SPIRIT Section  
 
SPIRIT 
Item 
No 
 
SPIRIT Item Description Addressed 
on page 
number# 
SPIRIT-PRO 
Item No 
SPIRIT PRO Extension Item Description 
 
Addressed 
on page 
number# 
Administrative 
information 
 
      
Title 1 Descriptive title identifying the study design, 
population, interventions, and, if applicable, trial 
acronym 
    
Trial registration 2a Trial identifier and registry name. If not yet 
registered, name of intended registry 
    
 2b All items from the World Health Organization Trial 
Registration Data Set 
    
Protocol version 3 Date and version identifier     
Funding 4 Sources and types of financial, material, and other 
support 
    
Roles and 
responsibilities 
5a Names, affiliations, and roles of protocol 
contributors 
 SPIRIT-5a-
PRO 
Elaboration 
 
Specify the individual(s) responsible for the PRO 
content of the trial protocol. 
 
 
 5b Name and contact information for the trial sponsor     
 5c Role of study sponsor and funders, if any, in study 
design; collection, management, analysis, and 
interpretation of data; writing of the report; and the 
decision to submit the report for publication, 
including whether they will have ultimate authority 
over any of these activities 
    
 5d Composition, roles, and responsibilities of the 
coordinating centre, steering committee, endpoint 
adjudication committee, data management team, 
and other individuals or groups overseeing the trial, 
if applicable (see Item 21a for data monitoring 
committee) 
    
Introduction       
 23 
 
 
Background and 
rationale 
6a Description of research question and justification for 
undertaking the trial, including summary of relevant 
studies (published and unpublished) examining 
benefits and harms for each intervention 
 SPIRIT-6a-
PRO 
Extension 
 
Describe the PRO specific research question and 
rationale for PRO assessment, and summarize PRO 
findings in relevant studies. 
 
 6b Explanation for choice of comparators     
Objectives 7 Specific objectives or hypotheses  SPIRIT-7-
PRO 
Extension 
 
State specific PRO objectives or hypotheses (including 
relevant PRO concepts/domains). 
 
Trial design 8 Description of trial design including type of trial (eg, 
parallel group, crossover, factorial, single group), 
allocation ratio, and framework (eg, superiority, 
equivalence, noninferiority, exploratory) 
    
Methods: 
Participants, 
interventions, and 
outcomes 
 
      
Study setting 9 Description of study settings (eg, community clinic, 
academic hospital) and list of countries where data 
will be collected. Reference to where list of study 
sites can be obtained 
    
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If 
applicable, eligibility criteria for study centres and 
individuals who will perform the interventions (eg, 
surgeons, psychotherapists) 
 SPIRIT-10-
PRO 
Extension 
 
Specify any PRO-specific eligibility criteria (eg, 
language/reading requirements or pre-randomization 
completion of PRO). If PROs will not be collected in 
the entire study sample, provide a rationale and 
describe the method for obtaining the PRO 
subsample. 
 
Interventions 11a Interventions for each group with sufficient detail to 
allow replication, including how and when they will 
be administered 
    
 11b Criteria for discontinuing or modifying allocated 
interventions for a given trial participant (eg, drug 
dose change in response to harms, participant 
request, or improving/worsening disease) 
    
 11c Strategies to improve adherence to intervention 
protocols, and any procedures for monitoring 
adherence (eg, drug tablet return, laboratory tests) 
    
 11d Relevant concomitant care and interventions that 
are permitted or prohibited during the trial 
    
Outcomes 12 Primary, secondary, and other outcomes, including 
the specific measurement variable (eg, systolic 
blood pressure), analysis metric (eg, change from 
baseline, final value, time to event), method of 
aggregation (eg, median, proportion), and time point 
 SPIRIT-12-
PRO 
Extension 
 
Specify the PRO concepts/domains used to evaluate 
the intervention (eg, overall HRQOL, specific domain, 
specific symptom) and, for each one, the analysis 
metric (eg, change from baseline, final value, time to 
event) and the principal time point or period of interest.  
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for each outcome. Explanation of the clinical 
relevance of chosen efficacy and harm outcomes is 
strongly recommended 
Participant timeline 13 Time schedule of enrolment, interventions 
(including any run-ins and washouts), assessments, 
and visits for participants. A schematic diagram is 
highly recommended (see Figure) 
 SPIRIT-13-
PRO 
Extension 
 
Include a schedule of PRO assessments, providing a 
rationale for the time points, and justifying if the initial 
assessment is not pre-randomization. Specify: time 
windows; whether PRO collection is prior to clinical 
assessments; and if using multiple questionnaires, 
whether order of administration will be standardized.  
 
Sample size 14 Estimated number of participants needed to achieve 
study objectives and how it was determined, 
including clinical and statistical assumptions 
supporting any sample size calculations 
 SPIRIT-14-
PRO 
Elaboration 
 
Where a PRO is the primary endpoint, state the 
required sample size (and how it was determined) and 
recruitment target (accounting for expected loss to 
follow-up). If sample size is not established based on 
PRO endpoint, then discuss the power of the principal 
PRO analyses. 
 
Recruitment 15 Strategies for achieving adequate participant 
enrolment to reach target sample size 
    
Methods: 
Assignment of 
interventions (for 
controlled trials) 
 
      
Allocation: 
 
      
Sequence 
generation 
16a Method of generating the allocation sequence (eg, 
computer-generated random numbers), and list of 
any factors for stratification. To reduce predictability 
of a random sequence, details of any planned 
restriction (eg, blocking) should be provided in a 
separate document that is unavailable to those who 
enrol participants or assign interventions 
    
Allocation 
concealment 
mechanism 
16b Mechanism of implementing the allocation 
sequence (eg, central telephone; sequentially 
numbered, opaque, sealed envelopes), describing 
any steps to conceal the sequence until 
interventions are assigned 
    
Implementation 16c Who will generate the allocation sequence, who will 
enrol participants, and who will assign participants 
to interventions 
    
Blinding (masking) 17a Who will be blinded after assignment to 
interventions (eg, trial participants, care providers, 
outcome assessors, data analysts), and how 
    
  17b If blinded, circumstances under which unblinding is 
permissible, and procedure for revealing a 
participant’s allocated intervention during the trial 
    
Methods: Data 
collection, 
      
 25 
 
management, and 
analysis 
 
Data collection 
methods 
18a Plans for assessment and collection of outcome, 
baseline, and other trial data, including any related 
processes to promote data quality (eg, duplicate 
measurements, training of assessors) and a 
description of study instruments (eg, 
questionnaires, laboratory tests) along with their 
reliability and validity, if known. Reference to where 
data collection forms can be found, if not in the 
protocol 
 SPIRIT-
18a(i)-PRO 
Extension  
 
Justify the PRO instrument to be used, and describe 
domains, number of items, recall period, instrument 
scaling/scoring (eg, range and direction of scores 
indicating a good/poor outcome). Evidence of PRO 
instrument measurement properties, interpretation 
guidelines, and patient acceptability/burden should be 
provided or cited if available, ideally in the population 
of interest. State whether the measure will be used in 
accordance with any user manual and specify and 
justify deviations if planned. 
 
    SPIRIT-
18a(ii)-PRO 
Extension  
 
Include a data collection plan outlining the permitted 
mode(s) of administration (eg, paper, telephone, 
electronic, other) and setting (eg, clinic, home, other). 
 
    SPIRIT-
18a(iii)-PRO 
Extension  
Specify whether more than one language version will 
be used, and state whether translated versions have 
been developed using currently recommended 
methods. 
 
    SPIRIT-
18a(iv)-PRO 
Extension  
 
Where the trial context requires someone other than 
the trial participant to answer on their behalf (a proxy 
reported outcome), state and justify this. Provide/cite 
evidence of the validity of proxy assessment if 
available. 
 
 18b Plans to promote participant retention and complete 
follow-up, including list of any outcome data to be 
collected for participants who discontinue or deviate 
from intervention protocols 
 SPIRIT-
18b(i)-PRO 
Extension  
 
Specify PRO data collection and management 
strategies for minimising avoidable missing data. 
 
    SPIRIT-
18b(ii)-PRO 
Elaboration  
 
Describe the process of PRO assessment for 
participants who discontinue or deviate from their 
assigned intervention protocol. 
 
Data management 19 Plans for data entry, coding, security, and storage, 
including any related processes to promote data 
quality (eg, double data entry; range checks for data 
values). Reference to where details of data 
management procedures can be found, if not in the 
protocol 
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Statistical methods 20a Statistical methods for analysing primary and 
secondary outcomes. Reference to where other 
details of the statistical analysis plan can be found, 
if not in the protocol 
 SPIRIT-20a-
PRO 
Elaboration 
 
State PRO analysis methods including any plans for 
addressing multiplicity/type 1 (α) error.      
 
  20b Methods for any additional analyses (eg, subgroup 
and adjusted analyses) 
    
  20c Definition of analysis population relating to protocol 
non-adherence (eg, as randomised analysis), and 
any statistical methods to handle missing data (eg, 
multiple imputation) 
 SPIRIT-20c-
PRO 
Elaboration 
 
State how missing data will be described and outline 
the methods for handling missing items or entire 
assessments (eg, approach to imputation and 
sensitivity analyses). 
 
Methods: 
Monitoring 
 
      
 21a Composition of data monitoring committee (DMC); 
summary of its role and reporting structure; 
statement of whether it is independent from the 
sponsor and competing interests; and reference to 
where further details about its charter can be found, 
if not in the protocol. Alternatively, an explanation of 
why a DMC is not needed 
 
    
 21b Description of any interim analyses and stopping 
guidelines, including who will have access to these 
interim results and make the final decision to 
terminate the trial 
    
Harms 22 Plans for collecting, assessing, reporting, and 
managing solicited and spontaneously reported 
adverse events and other unintended effects of trial 
interventions or trial conduct 
 SPIRIT-22-
PRO 
Extension 
 
State whether or not PRO data will be monitored 
during the study to inform the clinical care of individual 
trial participants and, if so, how this will be managed in 
a standardized way. Describe how this process will be 
explained to participants, eg, in the participant 
information sheet and consent form.  
 
Auditing 23 Frequency and procedures for auditing trial 
conduct, if any, and whether the process will be 
independent from investigators and the sponsor 
    
Ethics and 
dissemination 
 
      
Research ethics 
approval 
24 Plans for seeking research ethics 
committee/institutional review board (REC/IRB) 
approval 
    
Protocol 
amendments 
25 Plans for communicating important protocol 
modifications (eg, changes to eligibility criteria, 
outcomes, analyses) to relevant parties (eg, 
investigators, REC/IRBs, trial participants, trial 
registries, journals, regulators) 
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1, 2, 33
Consent or assent 26a Who will obtain informed consent or assent from 
potential trial participants or authorised surrogates, 
and how (see Item 32) 
    
  26b Additional consent provisions for collection and use 
of participant data and biological specimens in 
ancillary studies, if applicable 
    
Confidentiality 27 How personal information about potential and 
enrolled participants will be collected, shared, and 
maintained in order to protect confidentiality before, 
during, and after the trial 
    
Declaration of 
interests 
28 Financial and other competing interests for principal 
investigators for the overall trial and each study site 
    
Access to data 29 Statement of who will have access to the final trial 
dataset, and disclosure of contractual agreements 
that limit such access for investigators 
    
Ancillary and post-
trial care 
30 Provisions, if any, for ancillary and post-trial care, 
and for compensation to those who suffer harm 
from trial participation 
    
Dissemination 
policy 
31a Plans for investigators and sponsor to communicate 
trial results to participants, healthcare professionals, 
the public, and other relevant groups (eg, via 
publication, reporting in results databases, or other 
data sharing arrangements), including any 
publication restrictions 
    
  31b Authorship eligibility guidelines and any intended 
use of professional writers 
    
  31c Plans, if any, for granting public access to the full 
protocol, participant-level dataset, and statistical 
code 
    
Appendices 
 
      
Informed consent 
materials 
32 Model consent form and other related 
documentation given to participants and authorised 
surrogates 
    
Biological 
specimens 
33 Plans for collection, laboratory evaluation, and 
storage of biological specimens for genetic or 
molecular analysis in the current trial and for future 
use in ancillary studies, if applicable 
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